For more than a decade, federal policy has assumed that making hospital prices visible will foster competition and curb costs. Transparency initiatives, reflected in disclosure rules and recent legislation, aim to give buyers a clearer view of pricing. Despite these efforts, commercial hospital charges continue to rise far beyond what underlying costs or quality improvements would justify.
The premise that publishing prices alone creates market discipline is flawed because hospitals set the prices while insurers act as price takers. In many metropolitan areas, consolidation has eliminated competition, leaving dominant hospital systems with unchecked pricing power. Buyers cannot remove these systems from their networks without violating regulatory requirements, so the prices posted simply reflect the leverage the sellers hold.
Disclosed price data often lacks reliability, with compliance dropping to about one in five hospitals. The posted figures vary widely in format—fixed amounts, per diems, case rates, and percentage discounts—making them noisy and incomparable. This inconsistency further undermines the effectiveness of transparency as a tool for price control.
Attempts to correct pricing through internal benchmarks frequently backfire. Statutory caps that tie commercial payments to a multiple of Medicare create a ceiling that prices climb toward. Regional medians and unilateral reference pricing lock in past pricing power, while internal reference pricing merely replicates the captured levels it seeks to escape.
The root of inflated hospital bills lies in provenance: prices set by the seller without an external benchmark. A professional fee on a hospital bill is tied to a national relative‑value scale and remains close to a fixed Medicare ratio, whereas the facility fee is written directly by the hospital and can exceed Medicare by large margins. Because the facility fee answers to no outside reference, it can vary dramatically for identical procedures.
Government policy has long used external benchmarks in pharmaceutical pricing, tying Medicare reimbursement to international prices. The same logic can apply to hospital facility fees, where no research and development costs justify the gap between U.S. commercial charges and foreign rates for similar surgeries.
External reference pricing restores a buyer’s leverage by providing an objective benchmark that the seller did not set. It does not require patient travel; instead, it serves as a contractual tool that sets a clear payment standard based on domestic or international comparators. This benchmark creates a credible outside option that influences negotiated rates.
Empirical evidence supports this approach. When a public employee retirement system set a reference price for joint replacements, most savings came from high‑priced hospitals voluntarily lowering rates. A supermarket chain that offered an international surgical option saw local hospitals cut prices within weeks, without any employees traveling abroad.
For self‑funded plans, fiduciary duty under ERISA requires a prudent evaluation of whether expenses are reasonable. Recent court rulings hold plan administrators accountable for paying excessive claims without a documented comparative process. Thus, external reference pricing is not only a cost‑saving strategy but also a legal safeguard.
To be effective and compliant, external reference prices must be pre‑negotiated, embedded in plan documents, and insured through stop‑loss carriers. This structure separates structured pricing from unconsented claim reductions, which can expose patients to balance billing and create liabilities that insurers refuse to cover.
In short, transparency alone merely displays the price tag on an unavoidable bill. By anchoring negotiations to externally sourced benchmarks, self‑funded plans can regain bargaining power, meet fiduciary obligations, and compel consolidated health systems to accept disciplined rates.
